LIXTE (LIXT) director receives 25,000 RSU equity grant

Rhea-AI Filing Summary

Porter Stuart D reported acquisition or exercise transactions in this Form 4 filing.

LIXTE BIOTECHNOLOGY HOLDINGS, INC. director Stuart D. Porter reported receiving an equity grant of 25,000 shares of common stock in the form of restricted share units. The grant was made at a stated price of $0.00 per share, reflecting stock-based compensation rather than a market purchase.

The 25,000 RSUs were granted under the company’s 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The RSUs vest 25% on May 29, 2026, and 25% on the last date of each subsequent calendar quarter until fully vested. Following this grant, Porter directly holds 25,000 shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Porter Stuart D

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	25,000	$0.00	--

Holdings After Transaction: Common Stock — 25,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSUs granted: 25,000 units Grant price: $0.00 per share Post-transaction holdings: 25,000 shares +2 more

5 metrics

RSUs granted 25,000 units Restricted share units granted to director Porter

Grant price $0.00 per share Stock-based compensation, not a cash purchase

Post-transaction holdings 25,000 shares Common stock held directly after the grant

Initial vesting date May 29, 2026 25% of RSUs vest on this date

Vesting cadence 25% each quarter-end On last date of each subsequent calendar quarter

Key Terms

restricted share units ("RSUs"), 2020 Stock Incentive Plan, contingent right, vesting

4 terms

restricted share units ("RSUs") financial

"Represents a grant of 25,000 restricted share units ("RSUs")."

2020 Stock Incentive Plan financial

"The RSUs were granted pursuant to the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan."

contingent right financial

"Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service."

vesting financial

"The RSUs shall vest 25% on May 29, 2026, and 25% on the last date of each subsequent calendar quarter thereafter until fully vested."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Porter Stuart D

(Last) (First) (Middle)

433 PLAZA REAL SUITE 275

(Street)

BOCA RATON FLORIDA 33432

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LIXTE BIOTECHNOLOGY HOLDINGS, INC. [ LIXT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/29/2026		A		25,000(1)	A	$0	25,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of 25,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The RSUs shall vest 25% on May 29, 2026, and 25% on the last date of each subsequent calendar quarter thereafter until fully vested.

	/s/ Stuart D. Porter	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did LIXT director Stuart D. Porter report on this Form 4?

Stuart D. Porter reported receiving a grant of 25,000 restricted share units of LIXTE common stock. These RSUs were awarded as stock-based compensation under the 2020 Stock Incentive Plan and carry a vesting schedule tied to his continued service as a director.

How many LIXT (LIXT) shares are covered by Porter’s RSU grant?

The grant covers 25,000 restricted share units, each representing one potential share of LIXTE common stock. The units convert into shares only as they vest over time, so Porter’s ability to receive all shares depends on continued service.

What is the vesting schedule for Stuart D. Porter’s LIXT RSUs?

The 25,000 RSUs vest 25% on May 29, 2026, with an additional 25% vesting on the last day of each subsequent calendar quarter. This continues until the entire grant fully vests, subject to Porter’s continued service with LIXTE.

Did Stuart D. Porter buy LIXT shares in the open market?

No, he did not buy shares in the open market. The Form 4 shows a grant coded as an acquisition (A), meaning the 25,000 RSUs were awarded as compensation at a stated price of $0.00 per share, not purchased for cash.

Under which plan were the LIXT RSUs granted to Stuart D. Porter?

The restricted share units were granted under the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. This plan is used to award equity-based compensation, aligning director incentives with shareholder interests through contingent rights to company stock.

How many LIXT shares does Stuart D. Porter hold after this RSU grant?

After the reported grant, Porter directly holds 25,000 shares of LIXTE common stock associated with this RSU award. These shares are issuable as the RSUs vest over time according to the specified quarterly vesting schedule.